(UTC-08:00) Pacific Time (US & Canada)
We will soon be accepting abstracts for TTLC26 — this is an opportunity to share your research, present innovative ideas, and engage with leaders in the field. Stay tuned for details on how to submit across a range of topics and disciplines!
Please review the submission frequently asked questions and guidelines carefully.
Dates
Event Type
Venue
Host
Oct
3
Abstract Submission Portal Opens
12:00 AM
Nov
18
Abstract Submission Deadline
12:00 AM
Dec
18
Abstract Notifications
12:00 AM
Jan
7
LBA Abstract Deadline
12:00 AM
Panel only seen by widget owner
Panel only seen by widget owner
Guidelines
Who can present an abstract?
Only abstract submissions presented by Fellows, Residents & Junior Faculty within two years of completing your final training (i.e. fellowship, post-doc, etc.) and from North America (Canada, USA) will be accepted. These fellowship, residence or faculty status restrictions only apply to the lead author/presenter, more senior faculty and pharma company employees may be included as co-authors.
What types of abstracts are accepted?
- Regular Abstract
- Definition: Original scientific research that summarizes work done and major research findings.
- Required sections for abstract submission:
- Introduction
- Methods
- Results
- Conclusions
- Clinical Trials in Progress
- Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.
- Required sections:
- Introduction
- Methods
- Optional sections:
- Results
- Conclusion
- Case Report
- Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient. Must include a minimum of three (3), but preferably five (5) cases.
- Required sections:
- Introduction including selective literature review
- Methods
- Results
- Conclusion
- Late-Breaking Abstract
- Definition:
- LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines.
- LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
- For abstracts that do not meet LBA requirements the authors will be given 5 business days to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.
- Submission requirements:
- Authors of LBA must submit an intent to submit an LBA abstract through the abstract portal by November 18, 2025 (23:59 PDT).
- Required sections for intent to submit an LBA, which must be submitted by the January 7, 2026 deadline:
- Explanation of why the abstract qualifies as late-breaking
- Introduction
- Methods, including applicable endpoints
- Types of anticipated analysis and data to be reported
- LBA Eligibility Review:
- The Committee will review all submissions with the intent to submit LBA abstracts after the regular abstract submission deadline of November 18, 2025. Authors of approved LBA applications will be notified and advised on the processes for submitting final data by January 7, 2026. Authors of abstracts not being accepted for LBA submissions will be notified and given 5 days to submit all available data before the abstract is re-classified as a regular abstract and included in the regular abstract review and scheduling process.
Is industry allowed to be in lead or senior author positions for abstract submissions?
Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract.
Are there restrictions towards industry authors presenting abstracts?
Industry/pharmaceutical/commercial authors are permitted to submit a poster or e-poster presentations. Only abstract submissions presented by Fellows, Residents & Junior Faculty within two years of completing your final training (i.e. fellowship, post-doc, etc.) and from North America (Canada, USA) will be accepted. These fellowship, residence or faculty status restrictions only apply to the lead author/presenter, more senior faculty and pharma company employees may be included as co-authors.
Is there a limit to the number of abstracts an author can submit?
No.
Is there a charge for abstract submission?
No.
Who holds the copyright for the abstracts?
The authors of the abstract, however, IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations.
Who holds the copyright for the presentation materials?
The authors, however, IASLC reserves the right to publish and sell copies/recordings of the presentation materials.
Is the presenting author required to be an IASLC member?
No.
Does the abstract submission need to be sponsored by an IASLC member?
No.
No search results found
Panel only seen by widget owner
Stay Connected
© 2025 International Association for the Study of Lung Cancer - IASLC TTLC 2026